LINC01116 is a critical component in the advancement of gefitinib-resistant non-small-cell lung carcinoma (NSCLC) by influencing the expression of IFI44, thus offering a novel treatment target for overcoming TKI resistance in NSCLC [63]. This evidence concerns the gene LINC01116 and non-small cell lung carcinoma.